【ESMO2023】
10/21のPresidential 1は5演題中4演題が肺がん🫁
どれも気になる💡

✅術前nivo+ケモ（CheckMate77T）

✅ALK+ NSCLC 術後アレクチニブ（ALINA）

✅ RET+ NSCLC 1st lineセルペルカチニブ vs Pembro＋ケモ

✅EGFR ex20ins 1st line アミバンタマブ＋ケモ vs ケモ（PAPILLON）

Data from the #BDTX1535 trial showed superior results to small molecule trials in development, particularly in patients after #osimertinib treatment.
However, specific genetic mutations not addressed in the BDTX-1535 trial (EGFR #T790M , #Ex20ins , #KRAS , #cMET amplification)

📢Camilo Caceres Galvis Estudios que cambian estándares PAPILLON #ESMO2023 . 🧍 con cáncer 🫁 no microcítico avanzado con mutaciones Ex20ins #EGFR Amivantamab-Quimioterapia Vs quimioterapia (dupleta con platino):
 ⬆️mPFS: 11.4 vs 6.7 meses
 ⬆️ ORR, DoR, PFS2.
📈Tendencia Os
🔐 EA aceptable

#ESMO23 ⏳<1 week
💥 Many practice changing trials @myesmo 💥

🧵1/...
🫁 Lung Cancer #NSCLC

👉🏼1L setting:
#MARIPOSA Amivantamab+Lazertinib vs Osi for #EGFR mut

#LIBRETTO -431 Selpercatinib vs Doublet CT+/-Pembro for #RET

#PAPILLON Amivantamab+CT vs CT for #EGFR Ex20ins

B843.日本🇯🇵原装进口，莫博替尼-TAK-788
首款靶向EGFR ex20ins突变的小分子口服TKI
武田在今年世界肺癌大会上公布了Mobocertinib临床3项重要研究结果，第一项研究评估了Mobocertinib在EGFR ex20ins突变转移性NSCLC患者中的疗效和安全性

E123.印度🇮🇳原装进口，莫博替尼-TAK-788
首款靶向EGFR ex20ins突变的小分子口服TKI
武田在今年世界肺癌大会上公布了Mobocertinib临床3项重要研究结果，第一项研究评估了Mobocertinib在EGFR ex20ins突变转移性NSCLC患者中的疗效和安全性

B843.日本🇯🇵原装进口，莫博替尼-TAK-788
首款靶向EGFR ex20ins突变的小分子口服TKI
武田在今年世界肺癌大会上公布了Mobocertinib临床3项重要研究结果，第一项研究评估了Mobocertinib在EGFR ex20ins突变转移性NSCLC患者中的疗效和安全性，结果显示，在PPP队列中，无论患者既往是否接受过PD-1/PD-L1单抗

EGFR exon20ins+ NSCLC is a major unmet need. Sunvozertinib is a powerful ex20ins-active TKI, ORR 60% and managable safety profile. Good news for patients!

【Uncommon EGFR変異（ex20ins,T790M以外）とTKIの効果】

📚JTO 2024
x.gd/3sKaT

📈Systematic review(n=1836, 38試験)

✔︎G719X、S768I、E709X、L747X、複合変異に対する2G-TKI(Afa)の奏効は1G/3Gよりも高い

✔︎その他の稀な変異(L861Q等)に対しては3G-TKI(Osi)も考慮可能

1/2

NOW ENROLLING: Champions' new #EGFR Mutant In Vivo Screen featuring 30 unique PDX models including #T790M , #L858R , #C797S , #ex19del , #ex20ins mutations and models resistant to #osimertinib , #erlotinib , #gefitinib , #afatinib , #CPI .
Enroll by August 31st: hubs.li/Q01WYBP80

CLOSING SOON: Champions' new #EGFR Mutant In Vivo Screen featuring 30 unique PDX models including #T790M , #L858R , #C797S , #ex19del , #ex20ins mutations and models resistant to #osimertinib , #erlotinib , #gefitinib , #afatinib , #CPI .
Enroll by August 31st: hubs.li/Q01_0NBr0

#莫博赛替尼
#莫博替尼
#mobocertinib
#moboxen
#anticancer
#lungcancer
#exkivity
#moboxen 40mg
Moboxen (Mobocertinib), Exkivity 是一种用于治疗肺癌的处方药。 Mobocertinib 是针对 EGFR ex20ins+ NSCLC 的一项尚未实现的突破。

website : medicine-international.com

Don't miss out on Dr Jo Raskin 👨‍⚕️🌻's latest updates: LEAD trial unveils enhanced immune response with RT, savolitinib's potential with METex14 NSCLC, and insights from PAPILLON and BECOME studies on EGFR Ex20ins NSCLC treatment. Plus, CHECKMATE 77T analysis offers fresh

日本原装进口，莫博替尼-TAK-788
首款靶向EGFR ex20ins突变的小分子口服TKI
武田在今年世界肺癌大会上公布了Mobocertinib临床3项重要研究结果，第一项研究评估了Mobocertinib在EGFR ex20ins突变转移性NSCLC患者中的疗效和安全性，结果显示，在PPP队列中，无论患者既往是否接受过PD-1/PD-L1单抗治疗

#ASCO23 #LCSM
📢 Safety and efficacy of YK-029A, a new EGFR TKI, in advanced NSCLC with ex20ins, T790M or rare mutations 👩‍🔬🧪.
➡️ Phase 1 trial, 108 patients 🧑‍🤝‍🧑.
➡️ Most common TRAEs: diarrhea (46.3%), anemia (38.0%), and rash (32.4%) 🌡️. ➡️ For the EGFR ex20ins cohort, objective

Although it’s cold and rainy in Copenhagen, feeling the heat in #ELCC23 lung cancer conference. A big discrepancy in audiences in choosing 1st line therapy for EGFR ex20ins LUAD. Speaker Dr Girard chose chemo+bev to avoid immunotherapy. ESMO - Eur. Oncology IASLC

Abstract 9119: FDA analysis of toxicity profiles of oral TKIs (RET, EGFR ex20ins, KRAS G12C, MET skip, and RET) recently approved for NSCLC based on receipt of prior ICI therapy by Dr. Yufan Liu. Grade 3-4 AEs, SAEs, and hepatotoxicity were slightly higher. #ASCO23 #LCSM